Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing medicines for patients and families living with epilepsies and seizure-related neurological disorders. The Company is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. The Company’s genetic research programs include OV815 and OV825 and OV882. OV815 focuses on the mutations associated with KIF1A-associated neurological disorder (KAND). OV825 has advanced to candidate lead identification for the rare neurodevelopmental condition HNRNPH2. OV882 is a short hairpin RNA that the Company is evaluating as a potential disease-modifying gene therapy for Angelman syndrome. OV329 is an investigational, next-generation GABA-AT inhibitor that the Company is developing for the treatment of adult and pediatric epilepsy disorders.